PTCT
PTC Therapeutics, Inc.NASDAQHealthcare$67.77-1.43%ClosedMarket Cap: $5.61B
As of 2026-04-06
Valuation
P/E (TTM)
8.22
PEG
0.03
P/B
-27.08
P/S
3.30
EV/EBITDA
5.87
DCF Value
$-494.94
FCF Yield
12.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.0%
Operating Margin
49.5%
Net Margin
39.4%
ROE
-362.4%
ROA
23.4%
ROIC
37.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $164.7M | 90.1% | $-81.6M | $-135.0M | $-1.67 | — |
| FY 2025 | $1.73B | 95.9% | $856.5M | $682.6M | $7.78 | — |
| Q3 2025 | $211.0M | 45.1% | $3.0M | $15.9M | $0.20 | — |
| Q2 2025 | $178.9M | 93.6% | $-35.0M | $-64.8M | $-0.83 | — |
| Q1 2025 | $1.18B | 98.9% | $970.2M | $866.6M | $10.04 | — |
| Q4 2024 | $213.2M | 92.4% | $-162.4M | $-65.9M | $-0.85 | — |
| FY 2024 | $806.8M | 92.9% | $-302.6M | $-363.3M | $-4.73 | — |
| Q3 2024 | $196.8M | 94.5% | $-54.5M | $-106.7M | $-1.39 | — |
| Q2 2024 | $186.7M | 91.7% | $-40.2M | $-99.2M | $-1.29 | — |
| Q1 2024 | $210.1M | 93.0% | $-45.5M | $-91.6M | $-1.20 | — |
| Q4 2023 | $307.1M | 65.4% | $3.1M | $-155.8M | $-2.06 | — |
| FY 2023 | $937.8M | 93.0% | $-439.5M | $-626.6M | $-8.37 | — |